Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sumoylated PPARα mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice
Nicolas Leuenberger, … , Sylvain Pradervand, Walter Wahli
Nicolas Leuenberger, … , Sylvain Pradervand, Walter Wahli
Published September 1, 2009
Citation Information: J Clin Invest. 2009;119(10):3138-3148. https://doi.org/10.1172/JCI39019.
View: Text | PDF
Research Article Genetics

Sumoylated PPARα mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice

  • Text
  • PDF
Abstract

As most metabolic studies are conducted in male animals, understanding the sex specificity of the underlying molecular pathways has been broadly neglected; for example, whether PPARs elicit sex-dependent responses has not been determined. Here we show that in mice, PPARα has broad female-dependent repressive actions on hepatic genes involved in steroid metabolism and immunity. In male mice, this effect was reproduced by the administration of a synthetic PPARα ligand. Using the steroid oxysterol 7α-hydroxylase cytochrome P450 7b1 (Cyp7b1) gene as a model, we elucidated the molecular mechanism of this sex-specific PPARα-dependent repression. Initial sumoylation of the ligand-binding domain of PPARα triggered the interaction of PPARα with GA-binding protein α (GABPα) bound to the target Cyp7b1 promoter. Histone deacetylase and DNA and histone methylases were then recruited, and the adjacent Sp1-binding site and histones were methylated. These events resulted in loss of Sp1-stimulated expression and thus downregulation of Cyp7b1. Physiologically, this repression conferred on female mice protection against estrogen-induced intrahepatic cholestasis, the most common hepatic disease during pregnancy, suggesting a therapeutic target for prevention of this disease.

Authors

Nicolas Leuenberger, Sylvain Pradervand, Walter Wahli

×

Figure 3

The AF-2 domain is essential for PPARα repression of Cyp7b1.

Options: View larger image (or click on image) Download as PowerPoint
The AF-2 domain is essential for PPARα repression of Cyp7b1.
   
(A) Sch...
(A) Schematic representation of PPARα-modulated androgen production through regulation of Cyp7b1 in females (F). (B) Age-matched female and male WT and PPARα-null mice were treated with WY-14643 for 5 days, and hepatic Cyp7b1 expression was measured by quantitative real-time PCR (n = 6 per group) and (C) Western blotting. (D) Cotransfection of luc-reporter gene driven by a 1,086-bp CYP7B1 promoter fragment [pCYP7B1-luc(–1086/+189bp)] and mouse PPARα expression vector. 3X-PPRE-TK-Luc was used as a positive control. (E) The LBDα or N-terminal domain of PPARα was fused to the Gal4 DBD. The chimeras were cotransfected with the pCYP7B1-luc reporter gene. 5X-UAS-TK-Luc was used as a control for the activity of the PPARα N-terminal domain and LBD chimera (n = 4 per group). (F) PPARα lacking the 13 C-terminal amino acids (PPARαΔC13) failed to repress pCYP7B1-luc activity. (C–E) After transfection, cells were treated with WY-14643 (1 μM) or DMSO (vehicle; Control) for 20 hours. Values are presented as mean ± SEM (n = 3). *P ≤ 0.05, **P ≤ 0.01 versus control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts